Effects of Pharmacist-led Medication Reconciliation Services on Geriatric Patients

NCT06610292 | Completed

• 1 other identifier: 6/2018
• Study Type: interventional
• Target: 128
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to assess the effects of Pharmacist-led medication reconciliation on hospitalized elderly patients aged above 65 at a leading tertiary military hospital in Jordan.

Conditions

Geriatric Patients; Medication Reconcilitation Upon Hospital Admission; Medication Reconciliation At Discharge; Pharmacist-led Medication Reconciliation

Keywords

Medication reconciliation; Geriatrics; Geriatric patients; Jordan; Tertiary military hospital; Pharmacist-led medication reconciliation

Outcome Measures

Primary Outcomes (5)

• Describing prevalence and nature of medication discrepancies in elderly patients and investigating contributing factors to medication discrepancies.

  Linear regression analysis was performed to assess risk factors associated with the occurrence of medication discrepancies in elderly patients.

  Up to 20 weeks

• Analysis of the effects of Pharmacist-led medication reconciliation services on resolving medication discrepancies upon discharge

  Number of resolved medication discrepancies was documented upon discharge after providing pharmacist-led medication reconciliation services.

  Up to 16 weeks

• Evaluating the impacts of Pharmacist-led medication reconciliation services on hospital re-admissions within 30 days of discharge

  Elderly patients were assessed for number of hospital re-admissions within 30 days of discharge at control and intervention groups.

  Up to 20 weeks

• Evaluating the impacts of Pharmacist-led medication reconciliation services on emergency department visits within 30 days of discharge

  Elderly patients were assessed for number of emergency department visits within 30 days of discharge at control and intervention groups.

  Up to 20 weeks

• Evaluating the impacts of Pharmacist-led medication reconciliation services on medications side effects within 30 days of discharge

  Elderly patients were assessed for incidence of medications side effects within 30 days of discharge at control and intervention groups.

  Up to 20 weeks

Study Arms (2)

Control group

NO INTERVENTION

Patients did not receive Pharmacist-led medication reconciliation services

Intervention group

EXPERIMENTAL

Patients received Pharmacist-led medication reconciliation services

Other: Pharmacist-led medication reconciliation services

Interventions

Pharmacist-led medication reconciliation services OTHER

Upon admission, information about patients Best Possible Medication History (BPMH) was extracted. Information on current medications, both regular and as-needed, was also recorded. All data were cross-referenced with the electronic records and verified through patients or caregivers interviews to create a comprehensive medication list. Then, comparison was conducted between standard care medication list and Pharmacist-led medication reconciliation list to identify any possible medication discrepancies. Also, during hospital stay and upon discharge emerging medication discrepancies were assessed and resolved. Moreover, the impacts on healthcare resources utilization within 30 days post-discharge was measured. This includes evaluating hospital re-admissions, emergency department visits, and the occurrence of any adverse drug events (ADEs).

Intervention group

Eligibility Criteria

• Age: 65 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)

You may qualify if:

• Newly admitted patient within no more than 24 hours and anticipated to stay in the hospital for more than 48 hours.
• Geriatrics patients defined as those aged (≥65 years) (Orimo et al., 2006).
• Prescribed at least one chronic medication prior to the study admission.

You may not qualify if:

• Patient admitted to the critical care or isolation units or in unconscious or comatose states.
• Patients if they were discharged against medical advice.

Sponsors & Collaborators

• University of Jordan: lead
• Jordanian Royal Medical Services: collaborator
• Royal Medical Services, Jordanian Armed Forces: collaborator

Study Sites (1)

University of Jordan

Amman, Jordan

Location

Study Officials

• Eman A Hammad

  Department of Biopharmaceutics and Clinical Pharmacy, School of Pharmacy, University of Jordan

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: CARE PROVIDER
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Research Assistant

Study Record Dates

• First Submitted: September 17, 2024
• First Posted: September 24, 2024
• Study Start: June 24, 2018
• Primary Completion: October 13, 2018
• Study Completion: October 13, 2018
• Last Updated: September 24, 2024

Record last verified: 2024-09

Data Sharing

• IPD Sharing: Will not share

Locations

JO (1)